For years, the longevity field has asked the FDA one question: does aging count? On October 1, 2026, it got its clearest answer yet. The answer was not a yes, but it was not a no either. At the 13th Aging Research and Drug Discovery Meeting (ARDD) at Harvard, four senior FDA officials joined a […]
Generative AI just cleared a bar no drug candidate has cleared before it. On September 7, 2026, Insilico Medicine published a study in Nature Biotechnology showing that rentosertib — the first drug ever discovered and designed end-to-end by generative AI — produced a consistent, measurable shift toward younger predicted biological age across six independently developed
The longevity industry is moving fast. On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax — for addition to the 503A Bulk Drug Substances list, the roster of ingredients licensed compounding pharmacies may legally prepare against a prescription. A
The FDA Just Voted on Peptides. Here’s What the Vote Actually Means Read More »